Davide Seruggia Group

Davide Seruggia Group

Davide Seruggia ©
Email: davide.seruggia(at)ccri.at

Pediatric Leukemia Biology

We study non-coding regulatory elements, chromatin modifiers and other epigenetic factors in the context of leukemia and other pediatric malignancies.

Team 

We are a team of molecular and computational biologists working at the boundaries between chromatin biology, genome editing and cancer. Our research is focused on two main areas:

NON-CODING REGULATORY SEQUENCES IN LEUKEMIA

Functional non-coding regions such as enhancers and insulators play an essential role in the regulation of cell type-specific gene expression programs, and mutations at non-coding elements can drive observable phenotypic changes comparable to those driven by mutations at coding sequences (see Seruggia et al. 2015Seruggia et al. 2020). However, due to lack of appropriate technology, just a limited number of disease-related regulatory sequences have been described, leaving many potential targets of therapy to be discovered. For these reasons, our goal is to investigate the contribution of non-coding sequences and 3D genome structure in cancer. We focus on pediatric leukemia and drug resistance. What is the role of enhancers in the acquisition of drug resistance? How chromatin topology affects gene expression in leukemia? What is the effect of sequence variation at enhancers whose mutation is associated with leukemia? We use epi/genome editing (CRISPR, CRISPRi, CRISPRa), chromatin profiling (ChIP-seq, Cut and Run, ATAC-seq) and computational biology to answer these questions. This project is funded by a Starting Grant from the ERC.

TFIID/SAGA COMPONENTS AS TARGETS IN MYC-DRIVEN PEDIATRIC CANCER

We previously reported a connection between two chromatin modifiers of the SAGA complex and self-renewal in mouse embryonic stem cells (see Seruggia et al 2019)We discovered that loss of Taf5l and Taf6l in mESCs results in a dramatic reduction in c-Myc expression at the RNA and protein levels. However, the functions of Taf5l and Taf6l in mESCs and other cell types, as well as their mechanism of action, remain unexplored. How do Taf5l and Taf6l control c-Myc expression and stem cell identity? Are these factors required in other types of stem cells, i.e. adult hematopoietic stem cells?  Can we harness vulnerabilities within the TFIID and SAGA members to treat MYC-driven malignancies? We use mouse modelsgenomics and genome editing to answer these questions.

Further information and news are available on our lab website. Interested in joining the team? Please get in touch stating your research interests and background.

Selected Articles

Full list of publications here

Team Pediatric Leukemia Biology

Dr. Davide Seruggia (PhD)

Dr. Davide Seruggia (PhD)

Principal Investigator

davide.seruggia(at)ccri.at +43 1 40470 4030

Anzhelika Karjalainen (MSc)

Anzhelika Karjalainen (MSc)

Lab Manager / TA

anzhelika.karjalainen(at)ccri.at +43 1 40470 0